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Abstract
Background. Preclinical studies suggest that skull remodeling surgery (SR-surgery) increases the dose of tumor 
treating fields (TTFields) in glioblastoma (GBM) and prevents wasteful current shunting through the skin. SR-surgery 
introduces minor skull defects to focus the cancer-inhibiting currents toward the tumor and increase the treatment 
dose. This study aimed to test the safety and feasibility of this concept in a phase I setting.
Methods: Fifteen adult patients with the first recurrence of GBM were treated with personalized SR-surgery, 
TTFields, and physician’s choice oncological therapy. The primary endpoint was toxicity and secondary endpoints 
included standard efficacy outcomes.
Results: SR-surgery resulted in a mean skull defect area of 10.6 cm2 producing a median TTFields enhancement 
of 32% (range 25–59%). The median TTFields treatment duration was 6.8 months and the median compliance rate 
90%. Patients received either bevacizumab, bevacizumab/irinotecan, or temozolomide rechallenge. We observed 
71 adverse events (AEs) of grades 1 (52%), 2 (35%), and 3 (13%). There were no grade 4 or 5 AEs or intervention-
related serious AEs. Six patients experienced minor TTFields-induced skin rash. The median progression-free 
survival (PFS) was 4.6  months and the PFS rate at 6  months was 36%. The median overall survival (OS) was 
15.5 months and the OS rate at 12 months was 55%.
Conclusions: TTFields therapy combined with SR-surgery and medical oncological treatment is safe and nontoxic 
and holds the potential to improve the outcome for GBM patients through focal dose enhancement in the tumor.
Key Points
 • Craniectomy and small burr holes in the skull focally enhance the dose of TTFields.
 • Craniectomy is safe in combination with TTFields and not a contraindication.
 • TTFields in combination with craniectomy or small burr holes is safe and likely effective.
Glioblastoma (GBM) is the most prevalent and severe pri-
mary adult brain cancer. Despite maximum safe resection, ra-
diotherapy, and chemotherapy, the prognosis is dismal with a 
median overall survival (OS) of approximately 1 year for newly 
diagnosed cases.1–4 Recently, tumor treating fields (TTFields, 
Optune) were included as a Category 1 recommendation 
OptimalTTF-1: Enhancing tumor treating fields therapy 
with skull remodeling surgery. A clinical phase I trial in 
adult recurrent glioblastoma
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for patients with newly diagnosed GBM by the National 
Comprehensive Cancer Network in the United States.5 
TTFields are low-intensity (1–3 V/m) and intermediate fre-
quency (200  kHz) alternating fields that disrupt mitosis 
and inhibit tumor growth.6 A recent randomized controlled 
phase 3 trial (EF-14) established that TTFields result in a 
sustained OS benefit (OS = 20.9 vs 16.0 months, P < .001) 
and prolonged progression-free survival (PFS  =  6.7 vs 
4.0 months, P < .001) for newly diagnosed GBM when added 
to temozolomide maintenance therapy.7 Although efficacy 
benefits have been less profound for recurrent GBM (rGBM), 
a randomized controlled phase 3 trial (EF-11) has demon-
strated superior toxicity for TTFields monotherapy com-
pared to best practice medical oncological therapy alone.8 
Subsequent retrospective studies and a meta-analysis have 
since indicated a significant survival benefit for both recur-
rent and newly diagnosed GBM.9,10
TTFields Dosimetry and Dose 
Enhancement With Skull 
Remodeling Surgery
Different methods have been implemented to quantify 
the dose distribution of TTFields in the brain and provide 
strategies for treatment planning and response prediction. 
Although the efficacy of TTFields is influenced by multiple 
factors, such as frequency and spatial correlation of the 
fields,6,11,12 the field intensity distribution is commonly ac-
cepted as a surrogate measure of treatment dose. The field 
intensity correlates positively with the tumor kill rate in 
vitro6 and the OS, that is, high field intensities in the tumor 
lead to longer OS.13 The field distribution can be estimated 
using finite element methods14–17 based on personalized 
computational models constructed from MRI data, see 
Refs 18 and 17 for further details on TTFields dosimetry and 
its clinical implications.
Using dosimetry methods, we previously showed that skull 
remodeling surgery (SR-surgery), including burr holes and 
minor craniectomies placed above the tumor region, pro-
vide a substantial (~70%) and highly focused enhancement of 
TTFields in the tumor without affecting the dose in the healthy 
tissues (Figure 1G).14 The skull defects serve as low-resistance 
pathways that facilitate current flow into the tumor region 
(Figure  1D) and prevent wasteful shunting of currents 
through the skin between the arrays, caused by shielding 
effects of the high-impedance skull (Figure 1C and E).
Here, we present the results of a proof-of-concept phase 
I clinical trial testing SR-surgery as a rational, innovative, 
and dose-enhancing method to improve TTFields therapy 
against rGBM.
Methods
The trial was a prospective, open-label, single-center 
phase I trial investigating safety, feasibility, and prelimi-
nary efficacy of SR-surgery in combination with TTFields 
and best choice chemotherapy for rGBM (clinicaltrials.
gov id NCT02893137). The study was performed at Aarhus 
University Hospital, Denmark, in the period October 1, 
2016 to May 31, 2019. All study procedures were in accord-
ance with the ethical standards of the Helsinki Declaration 
of the World Medical Association19 and followed guidelines 
for Good Clinical Practice (ICH-GCP), ISO-14155 stand-
ards, and relevant Danish regulations, see Supplementary 
Material S1 for further protocol details.
Eligibility and Enrollment
Inclusion criteria were (1) age ≥18 years, (2) histopatholog-
ical primary diagnosis of GBM using the WHO 2016 classifi-
cation,20 (3) estimated survival ≥3 months, (4) supratentorial 
tumor location, (5) not a candidate for further radiotherapy, 
(6) first disease progression according to RANO criteria21 
based on MRI performed no later than 4 weeks prior to en-
rollment, (7) Karnofsky performance score (KPS) ≥70, (8) 
ability to comply with TTFields, (9) significant expected ben-
efit from feasible SR-surgery combined with TTFields, that 
is, (a) focal disease and (b) at least some part of the tumor 
or resection cavity had to be closer than 2 cm from the brain 
surface, and (10) signed written consent form.
Exclusion criteria were (1) pregnancy or nursing, (2) 
less than 4 weeks since radiation therapy, (3) infratentorial 
tumor, (4) implanted pacemaker, (5) programmable shunts, 
(6) deep brain stimulator, (7) refractory symptomatic 
Importance of the Study
We present phase I data for a new, rational, 
and innovative intervention combining tumor 
treating fields (TTFields) with targeted skull 
remodeling surgery to enhance the field dose 
and clinical efficacy against recurrent glioblas-
toma. The concept builds on preclinical dosim-
etry studies and recent clinical evidence that 
the field dose correlates with overall survival. 
Our study is the first to successfully achieve a 
significant and personalized TTFields dose ac-
cumulation focally in the tumor and we have 
used dosimetry methods to illustrate the con-
cept and its impact. The treatment is easy to 
understand and implement and potentially ex-
tends to all intracranial applications of TTFields. 
Our data suggest that the treatment is safe and 
effective (median overall survival 15.5 months 
and progression-free survival rate at 6 months 
is 36%). Based on these results, we have ini-
tiated a subsequent prospective randomized 
phase 2 clinical trial scheduled to begin recruit-
ment in summer 2020 (NCT04223999).
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epilepsy, (8) contraindications for SR-surgery, for example, 
bleeding diathesis or severe infection, (9) significant 
comorbidities, that is, significant liver function impairment, 
significant renal impairment, coagulopathy, thrombocyto-
penia, neutropenia, anemia, and (10) active participation in 
another therapeutic interventional clinical trial.
Patients were also excluded if rGBM could not be con-
firmed on histopathological examination of resected tissue 
after inclusion.
Treatment Plan
All patients were treated with SR-surgery, TTFields, and 
physician’s choice medical oncological therapy.
SR-surgery and resection
The objective of the SR-surgery was to maximize the field 
intensity (ie, dose) in the residual tumor or the region sur-
rounding the resection cavity. The SR-surgery configuration 
was optimized for each individual (see Figure  2 for ex-
amples) by calculating the personalized field distributions 
before and after different virtual SR-configurations (eg, 
size, shape, and position). Configurations were explored 
on a trial-and-error basis. In general, the skull holes were 
clustered in a relatively small region directly above the re-
section cavity, to ensure that the TTFields were focused to-
ward the underlying tumor. Due to the complexity of field 
estimation, with many individual factors influencing the 
results, it was not feasible to implement a specific dose-
escalation regimen (Supplementary Material S2 and Ref. 
22). Instead, we required the chosen SR-configuration to 
induce more than 25% enhancement of the average field 
dose in the tumor to justify any potential risk imposed on 
the patient due to the SR-surgery. Furthermore, we gener-
ally required the total skull defect area to be below 30 cm2 
as a safety limitation for mechanical brain protection. This 
area limit was exceeded at the request of 2 patients, as a 
larger defect induced greater field enhancement in these 
cases. The SR-surgery design was conducted prior to sur-
gery and implemented with neuronavigation.
Maximum safe resection was performed for all patients, 
although this was not an inclusion criterion. Surgeries 
resulting in measurable residual disease on the postop-
erative MRI (<72  h) according to the RANO criteria were 
classified as partial resections, whereas surgeries resulting 
in no residual disease or nonmeasurable residual disease 
were categorized as gross total resections.
TTFields therapy
TTFields therapy was initiated 4 weeks from surgery. 
Array layouts were planned to maximize the TTFields 
dose in the tumor.16 In a normal clinical setting, the 
TTFields array layout is planned using the CE-marked 
and FDA-approved NovoTAL (Novocure) software, which 
uses individual morphometric measures of the head size 
and tumor size/position to determine a suitable person-
alized layout. However, this approach was not appro-
priate for the present trial, because SR-surgery causes 
a redistribution of the electric field (Figure  2D), which 
is not accounted for by NovoTAL. We therefore planned 
the layouts using more general principles for layout per-
sonalization16,23 and TTFields dosimetry.15,24 Basically, we 
positioned the arrays such that a row of edge electrodes 
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Figure 1. Distributions of current density and field intensity before and after SR-surgery. Panel A shows the position of one array pair on the sur-
face of the patients head, while the craniectomy and underlying regions of interest (tumor, yellow; peritumoral border zone, blue) are shown in panel 
B. Craniectomy reduced the amount of current shunted through the skin between the arrays (panel C vs E) and redirects the current through the 
hole in the skull (panel D vs F) and toward the tumor. Panel G shows the change in field intensity induced on the surface of the brain. Craniectomy 
enhances the field intensity by approximately 300 V/m in the region of interest, while the dose in the surrounding brain tissue remains unaffected.
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Figure 2. Examples of SR-surgery. Panel A shows 3 examples of SR-surgery configurations illustrated with 3D reconstructions of the skull surface based 
on CT scans. Four burr holes of 15 mm diameter were used in the leftmost example, 7 burr holes of 18 mm diameter in the middle example, and a total elliptic 
craniectomy of 85 × 65 mm semi-axes in the rightmost example, respectively. In all cases, the skull defects were distributed above the resection cavity and 
its surrounding borders, as shown in panel B for the leftmost case in panel A. The representation in panel B generally shows the skull and tumor outline in 
the computational model for the (courtesy of Novocure, Ltd) with the skull surface shown in purple, the craniotomy bone flap in red (primary surgery) and 
dark red (repeated surgery), the craniotomy line in pink, the underlying tumor in blue, and the resection cavity in green. The transducer array layout 
is shown in the rightmost illustration in panel B with orange markings on the A/P pair. Panel C shows surface reconstructions of the field distribution be-
fore (left) and after (right) SR-surgery for the same patient. Parts of the figure are reproduced from Ref. 22. Panel D shows the difference in current density 
distribution before and after SR-surgery equivalent to the case in panels A (left), B, and C. Results are shown for the skin (left) and CSF (middle) surfaces, 
respectively, and for the L/R array pair only. It is evident, that a significant amount of current is shunted through the burr holes. The rightmost illustration in 
panel D shows the equivalent absolute difference in field distribution in the underlying brain. Finally, panel E shows the relationship between the total area 
of the skull defect for the individual SR-surgery configurations (cm2) and the corresponding relative field enhancement (%). Patients treated with TTFields 
(n = 11) are shown in blue and patients excluded prior to TTFields (n = 4) are shown in red.
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from one array in each pair overlaid the burr holes and 
tumor region (Figure 2B). This was done for both pairs so 
that one array from each pair overlapped the remodeled 
skull region. The rationale for the approach is that stronger 
fields are induced at the periphery of the arrays due to the 
“edge effect,” see Ref. 16 and Supplementary Material S3. 
Therefore, it was not desirable to place holes underneath 
the central parts of the arrays or far away from the array. 
The other array in the same pair was placed on the oppo-
site side of the skull so that the line between the paired 
arrays passed through the target regions of interest. This 
ensured that both array pairs contributed current flow 
through the skull holes, inducing high fields in the tumor 
throughout the entire duty cycle. Given the perpendic-
ular orientation of the 2 array pairs relative to each other, 
they covered different areas of the underlying tumor and 
brain region as previously described by Korshoej et al.23 
The virtual placement of electrodes was performed using 
the SimNIBS GUI and a custom Matlab script (Mathworks, 
Inc.).
Adjuvant medical treatment
Medical oncological treatment was initiated 2–4 weeks 
after surgery and included bevacizumab (10 mg/kg every 
2 weeks, 3 administrations per cycle) alone or in combina-
tion with either lomustine (90 mg/m2 every 6 weeks, one 
administration per cycle) or irinotecan (125 mg/m2 every 
4 weeks).25 Temozolomide rechallenge (200  mg/m2) was 
preferred for patients with MGMT-methylated tumors who 
had initially completed 6 cycles of adjuvant temozolomide 
therapy. We did not impose restrictions on supportive care. 
Corticosteroid administration was reduced to the min-
imum effective dose.26,27
Endpoint Assessment
The primary endpoint was the severity and frequency of 
AEs evaluated by the investigators using CTCAEv4.0.28
Secondary endpoints were median OS, PFS at 6 months 
(PFS6), median PFS, OS rate at 12  months (OS12), ob-
jective response rate, quality of life (QoL) score (EORTC 
QLQ-C30 and QLQ–BN20 questionnaires),29 cumulative 
corticosteroid dosage, and KPS decline. Treatment re-
sponse was evaluated by trained neuroradiologists and 
neuro-oncologists using the immunotherapy response as-
sessment in neuro-oncology (iRANO) criteria,30 to allow for 
the potential delayed response previously demonstrated 
for TTFields.27
Patient Follow-Up and Monitoring
Clinical examination, including QoL and toxicity assess-
ment, was conducted (1) at baseline, (2) postoperatively 
during admission, (3) before TTFields and medical onco-
logical therapy, and (4) regularly during adjuvant treat-
ment. MRI, clinical examination, and laboratory tests were 
conducted every 12 weeks during follow-up, while QoL and 
toxicity were assessed every 6 weeks.31 Additional exam-
inations were conducted upon suspected or validated 
progression.
Treatment Discontinuation, Patient Exclusion, 
and Trial Termination
TTFields therapy was discontinued upon (1) disease recur-
rence, that is, second overall disease recurrence, (2) grade 
3–5 serious AE (SAE) caused by the intervention, or (3) un-
acceptable AEs regardless of grade. Upon active request 
from the patient, TTFields therapy beyond progression 
was allowed on a compassionate use basis or in connec-
tion with continued medical treatment. Patients were ex-
cluded in the events of (1) death, (2) trial completion, (3) 
loss to follow-up, (4) withdrawal of consent, or (5) safety 
prohibiting further participation. The trial was terminated 
when the final patient was excluded and the necessary 
data had been acquired. Furthermore, the trial was set to 
stop in the occurrence of more than 8 SAEs attributed to 
the intervention.
Statistical Methods
The trial was exploratory and descriptive so we did not 
perform sample size calculations nor risk stratification 
(Supplementary Material S1). AEs were reported as the 
number and frequencies of patients experiencing a partic-
ular AE at least once at any grade. For ongoing AEs with 
a variable grade over time, for example, the variable in-
tensity of headache, we reported the AE as a single event 
with the highest grade observed. Time-to-event data (eg, 
OS and PFS) were calculated from the date of inclusion 
until the date of the event and censored in the case of pa-
tient exclusion. The resulting data were reported using 
the Kaplan–Meier method with median estimates and 
95% confidence intervals (CIs). Binomial data, such as 
  
Screened: 20
SR-surgery: 15 (4F/11M)
Received TTFields: 11 (2F/9M)
Follow-up: 15
Analysed for safety: 15
Analysed for efficacy: 11
Did not receive TTFields: 4
•  Withdrawal of consent: 1
•  Post-op infection: 1
•  Post-op cognitive dysfuncion: 1
•  Non-recurrence: 1
Excluded: 5
 •  KPS<  70: 2
 •  Declined: 3
Figure 3. Patient flow diagram.
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PFS6 and OS12, were reported including 95% CIs using 
the exact binomial distribution. TTFields compliance rates 
were calculated as the relative device on-time (%) in the 
total treatment period. KPS decline was calculated as the 
absolute difference between the KPS at progression and 
the KPS at TTFields initiation. The cumulative corticosteroid 
dose was calculated as a weighted average over the en-
tire inclusion period and expressed in methylprednisolone 
equivalents. QoL was expressed as the global, functional, 
and symptom scores according to the EORTC QLQ-C30 
and –BN20 guidelines. Electrical field estimates were cal-
culated and reported as described previously in the paper. 
The relative field enhancement caused by SR-surgery was 
calculated for each patient, as the increase in predicted 
field intensity after SR-surgery relative to the field intensity 
before SR-surgery, that is, (Eafter−Ebefore)/Ebefore.
Results
Patient Flow
Twenty patients were screened for participation in the 
period December 12, 2016 to April 25, 2018. Fifteen were 
enrolled and followed up until May 31, 2019 (Figure  3). 
Of those not enrolled, 3 had declined participation, while 
2 were excluded due to KPS less than 70. Of the 15 en-
rolled patients, 4 were excluded prior to TTFields therapy 
due to radionecrosis/non-recurrence, postoperative infec-
tion, neurodeficit (Gerstmann syndrome), and withdrawal 
of consent, respectively. The remaining 11 patients com-
pleted the trial with active TTFields therapy. Baseline data 
and treatment outline are given in Table 1. The median fol-
low-up period was 14.8 months (range 5.8–25.2 months). 
All patients were followed up until exclusion and none 
were lost to follow-up.
Reasons for discontinuation of treatment
TTFields was discontinued for 8 out of the 11 patients. 
All cases of permanent TTFields discontinuation oc-
curred due to disease progression. AEs did not result in 
discontinuation for any patient. Four patients continued 
TTFields therapy beyond progression. Two of these were 
on a compassionate use basis, while the other 2 also con-
tinued active medical treatment with temozolomide and 
bevacizumab, respectively. Three patients were still on ac-
tive TTFields at the end of the trial period.
Baseline Data and Treatment Exposure
We included 11 male patients and 4 female patients. All pa-
tients had IDH-wildtype tumors. Baseline characteristics 
of patients treated with TTFields are presented in Table 1 
along with the general treatment outline.
SR-surgery and tumor resection
For the 15 enrolled participants, the median time from 
inclusion to SR-surgery and resection was 6 days (range 
0–14 days). Figure 2 shows examples of 3 different config-
urations of SR-surgery of varying extensiveness, including 
a visualization of the field-enhancing effects induced by 
the most commonly employed configuration (4 × 15 mm 
diameter). Field enhancement of more than 25% could 
be obtained for all patients (Figure 2E). The SR-surgeries 
were technically feasible, easy to perform, and added less 
than 15 minutes of additional surgery time. Tumor resec-
tion was performed in all cases (see Table 1 for the extent 
of resection).
Of the 11 patients receiving TTFields, 3 had 4 burr holes 
of 15 mm diameter, 1 had 5 holes of 15 mm diameter, 4 
had 6 holes of 15 mm diameter, 1 had 5 peripheral 15 mm 
holes and 1 central 25 mm hole, 1 had 7 holes of 15 mm di-
ameter, and 1 had an elliptic craniectomy (semi-axis diam-
eters 85 × 65 mm).
Of the 4 patients excluded before TTFields therapy, 
2 had five 15 mm holes, 1 had eight 20 mm holes, and 1 
had a total craniectomy (60  × 50  mm). Two of these pa-
tients had gross total resection and 2 had nonmeasurable 
residual tumors.
The relationship between the SR-surgery configuration, 
for example, the size, arrangement, and number of burr 
holes, and the induced relative field enhancement was 
  
Table 1. Patient Characteristics and Treatment Outline
Basic Characteristics Estimate
Age in years, median (range) 57 (39–67)
Male/female (n) 9/2
Preoperative KPS, median (range) 90 (70–100)
MGMT methylation (n) 4
Tumor location (n)  
 Frontal 2
 Parietal 2
 Temporal 5
 Parieto-occipital 2
SR-surgery and TTFields Median (range)
Skull defect area (cm2) 10.5 (7–48)
Field intensity in the tumor (V/m) 173 (111–210)
Relative field enhancement (%) 32 (25–59)
Absolute field enhancement (V/m) 40 (28–69)
TTFields compliance rate (%) 90 (48–98)
TTFields duration (months) 7.6 (2.3–24.0)
Extent of resection N
No residual tumor 4
Nonmeasurable residual tumor 5
Measurable residual tumor 2
Medical treatment Estimate
Bevacizumab monotherapy (n) 8
Bevacizumab/irinotecan (n) 1
Temozolomide rechallenge (n) 2
Daily methylprednisolone dose  
in mg, median (range)
14.3 (0–50)
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highly complex (Figure 2E). Although a complete review 
of this relationship was beyond the scope of this study, 
we generally observed that identical configurations had 
different efficacy for different patients, for example, 6  × 
15 mm burr holes, 10.6 cm2, induced field enhancements 
in the wide range of 25–60%. The field enhancement ap-
peared to plateau around 55–60% when the total area of 
the skull holes was more than 15–20  cm2. There was no 
linear correlation between the relative field enhancement 
and the skull hole area (r2 = 0.55). Similarly, we observed 
no correlation between the absolute field intensity in 
the tumor after SR-surgery and the increase in absolute 
field intensity in the tumor after SR-surgery (r2 = 0.49 and 
r2 = 0.094, respectively). As a part of the scheduled prepa-
ration, dosimetry calculations were performed for all pa-
tients included in the trial (Figure 2E), that is, also the 4 
patients who did not proceed to TTFields therapy. Since 
all 15 included patients contribute information about the 
expected field enhancement and the potential correlation 
with SR size and configuration, we included all patients in 
the correlation analysis.
TTFields therapy and adjuvant medical treatment
Details of the TTFields treatment and adjuvant therapy 
are given in Table  1. Of all patients receiving TTFields, 
8 were treated with bevacizumab monotherapy (me-
dian number of cycles  =  5, range 2–16). One patient re-
ceived bevacizumab/irinotecan combination treatment (2 
cycles), while 2 patients were treated with temozolomide 
rechallenge (3 and 4 cycles, respectively). Of the 4 patients 
not treated with TTFields, 1 received supportive care only, 
2 bevacizumab monotherapy (6 and 9 cycles, respectively), 
  
Table 2. Frequency of Adverse Events
Type of AE Number of Patients With AEs
TTF (N = 11) No TTF (N = 4) Total (N = 15)
n % 95% CI n % 95% CI n % 95% CI
Neurological          
 Headache 9 81.8 48–98 0   9 60.0 32–84
 Speech disturbances 3 27.3 6.0–61 1 25.0 0.6–81 4 26.7 7.8–55
 Seizure 5 45.5 17–77 0   5 33.3 12–62
 Paresis 1 9.1 0.2–41 3 75.0 19–99 4 26.7 7.8–55
 Visual disturbances 2 18.2 2.3–52 0   2 13.3 1.7–41
 Neglect 1 9.1 0.2–41 0   1 6.7 0.2–32
 Memory disturbances 1 9.1 0.2–41 0   1 6.7 0.2–32
Regional          
 Skin rash 6 54.5 23–83 0   6 40.0 16–68
 Scalp ulceration 2 18.2 2.3–52 0   2 13.3 1.7–41
 Surgical wound infection 1 9.1 2.3–52 1 25.0 0.6–81 2 13.3 1.7–41
 Surgical wound rupture 2 18.2 6.0–61 1 25.0 0.6–81 3 20.0 4.3–48
 Shoulder pain 2 18.2 2.3–52 1 25.0 0.6–81 3 20.0 4.3–48
 Axillary abscess 1 9.1 0.2–41 0   1 6.7 0.2–32
Systemic          
 Fatigue 4 36.4 11–69 2 50.0 6.8–93 6 40.0 16–68
 Nausea 3 27.3 6.0–61 3 75.0 19–99 6 40.0 16–68
 Fever 3 27.3 6.0–61 2 50.0 6.8–93 5 33.3 12–62
 Diarrhea 3 27.3 6.0–61 0   3 20.0 4.3–48
 Constipation 2 18.2 2.3–52 0   2 13.3 1.7–41
 Abdominal pain 2 18.2 2.3–52 0   2 13.3 1.7–41
 Dehydration 1 9.1 0.2–41 0   1 6.7 0.2–32
 Deep vein thrombosis 1 9.1 0.2–41 0   1 6.7 0.2–32
 Corticosteroid withdrawal syndrome 1 9.1 0.2–41 0   1 6.7 0.2–32
 Abnormal ECG 1 9.1 0.2–41 0   1 6.7 0.2–32
The table shows the numbers and frequencies of patients experiencing the observed AEs. A patient is registered as having an AE, if the AE occurred 
at least once, regardless of severity. All observed AEs were of grades 1–3. Patients are separated into those treated with TTFields (left column) and 
those not treated with TTFields (middle column). The right column shows results for all patients collectively. Supplementary Tables S4 and S5 list a 
breakdown of the AE data into grades and causalities, respectively.
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and 1 bevacizumab/lomustine combination treatment (7 
cycles).
Of those experiencing progression during TTFields (ie, 
second total recurrence), 2 patients were reoperated, 5 
discontinued all treatment, 1 continued bevacizumab 
with the addition of irinotecan (3 cycles), 1 received 
temozolomide rechallenge (6 cycles), 1 continued 
bevacizumab in combination with lomustine (2 cycles), 
and 1 continued bevacizumab monotherapy (8 cycles). 
Of the 4 patients not receiving TTFields, 3 discontinued 
all treatment at progression in the trial (ie, second recur-
rence) and 1 received 2 cycles of temozolomide before 
discontinuation.
Outcomes
Adverse events
The observed AEs are presented in Table  2 and 
Supplementary Table S4 (grading) and Supplementary 
Table S5 (causality).
In total, we observed 71 AEs of which most were mild to 
moderate (grade 1 or 2). Considering all patients, 52%, 95% 
CI: 40–64%, of all AEs were strictly mild with a maximum 
grade of 1, while 35%, 95% CI: 24–48%, were moderate or 
below with a maximum grade of 2. We recorded 11 grade 
3 SAEs (13%, 95% CI: 7–23%), all unrelated to the interven-
tion, and no grade 4 or 5 SAEs. Most SAEs were neurolog-
ical (N = 5): Three were seizures, which required admission 
and occurred at progression in patients with prior seizures, 
1 experienced a severe headache, while 2 had progres-
sive focal deficits in connection with disease progression. 
Systemic SAEs were fatigue, deep vein thrombosis, and di-
arrhea all unrelated to the intervention.
Patients excluded prior to TTFields therapy, that is, 
within 4 weeks from inclusion, accounted for 19.0%, 
95% CI: 11–30%, of AEs. These were mainly neurolog-
ical deficits attributed to the disease itself or resection 
surgery, although one patient did experience a grade 3 
postoperative infection, which led to exclusion and re-
quired surgical revision. None of the surgical AEs could 
be directly attributed to the SR-surgery per se but rather 
to the general concept of open surgery, for example, in-
fection, or to tumor resection, for example, postopera-
tive deficits.
Neurological AEs accounted for 37%, 95% CI: 26–49%, 
of all AEs regardless of grade. The most common neu-
rological AEs were headache (n = 9), seizures (n = 5), and 
focal deficits (n  =  7). Headache was the most frequently 
observed AE overall, occurring in 60%, 95% CI: 32–84%, of 
all patients and exclusively in those treated with TTFields. 
A causal relationship between headache and TTFields was 
found in 3 cases, while 1 was related to surgery and 5 had 
unknown causes although unrelated to the intervention. 
Focal neurological deficits were caused by the disease or 
resection surgery and all seizures were attributed to dis-
ease and progression.
Systemic AEs accounted for 39%, 95% CI: 28–52%, and 
were generally associated with chemotherapy, GBM, or 
unknown causes. The most common systemic AEs were fa-
tigue (40% of patients, 95% CI: 16–68%), nausea (40% of pa-
tients, 95% CI: 16–68%), and fever (33% of patients, 95% CI: 
12–62%). Causality could not be firmly established in 15 of 
the 29 observed systemic AEs, although these were likely 
attributed to medical oncological treatment or GBM (eg, 
fever, nausea, and fatigue). No systemic AE was related to 
TTFields, 6 were caused by medical oncological treatment 
(nausea, abdominal pain, and diarrhea), 4 were caused by 
surgery (postoperative fatigue, nausea, and fever), while 3 
AEs had other causes, such as opiate administration or cor-
ticosteroid withdrawal.
Regional AEs accounted for 24%, 95% CI: 15–36%, of 
all cases and mainly comprised grade 1 and 2 skin rash 
(55% of TTFields-treated patients, 95% CI: 23–83%) and 
minor scalp ulcerations (18%, 95% CI: 2.3–52%). These 
manifestations only occurred in patients treated with 
TTFields and were observed with caution and easily 
managed with topical corticosteroids and short pauses 
(1–3  days) in TTFields. One patient had a poor compli-
ance rate of 48% on average due to recurring scalp ul-
cers. The patient had previously been treated repeatedly 
with antibiotics for pustulous acne and hidrosadenitis. 
The ulcers occurred with unchanged frequency and 
severity and also at distant locations unaffected by 
TTFields, for example, in the axillary and perineal re-
gions. One patient had a minor postoperative wound 
rupture with localized infection, which was successfully 
treated with minor wound revision in local anesthesia 
and oral antibiotics. This resulted in a 2-week delay of 
TTFields initiation but did not affect the remaining treat-
ment. One patient in the TTFields group had a minor 
wound rupture shortly after surgery, which was success-
fully treated with a single suture. There were no signs of 
infection and the complications did not affect the med-
ical oncological treatment or TTField.
No surgery inflicted AEs could be associated with the 
skull remodeling procedure per se, but rather represented 
common neurosurgical complications, for example, 
due to resection or complicated wound healing. Within 
the investigated range of SR-surgery, encompassing 
minor burr holes and large craniectomies, we did not ob-
serve particular toxicity limitations or reach an apparent 
  
Table 3. Efficacy Outcome Estimates
Outcome Estimate
Median OS, months 15.5 months, 95% CI: 9.4–NA
OS at 12 months, % 55%, 95% CI: 25–84
Median PFS, months 4.6 months, 95% CI: 4.1–NA
PFS rate at 6 months, % 36%, 95% CI: 8–64
Objective response rate, % ORR = 9.1%, 95% CI: 0.2–41.3
Methylprednisolone dose 
decline, mg
 
  Total, ie, from inclusion 
until progression
11.8 ± 19.4 mg
  Post-surgery, ie, from inclu-
sion until TTFields initiation
10.4 ± 14.3 mg
  TTFields, ie, from TTFields 
initiation until progression
1.45 ± 12.0 mg
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maximum-tolerated dose neither for the induced field in-
tensity nor for the introduced skull defects.
Efficacy outcomes
Survival estimates and efficacy outcomes are presented 
in Table  3. In general, the results were promising with 
longer OS (median OS  =  15.5  months, 95% CI: 9.4%–
NA) and PFS (PFS6  =  36%, 95% CI: 8–64%) estimates 
compared to historical data although the study was not 
powered for direct statistical comparison. Kaplan–Meier 
curves for OS and PFS are shown in Supplementary 
Figure S6.
Corticosteroid use, KPS, and QoL
The median daily methylprednisolone dose was 14.3 mg 
(range 0–50  mg) over the course of the trial. The mean 
total decline in steroid dose during the trial, that is, the 
presurgical dose at inclusion minus the dose at the time 
of progression, was considerable (11.8± 19.4  mg) with 
the most significant reduction occurring after surgery. 
Accordingly, the presurgical dose at inclusion was reduced 
by 10.4± 14.3 mg at the time of initiation of TTFields and 
oncological treatment and further by 1.45 ± 12.0 mg at the 
time of disease progression (Table 3). Three out of the 11 pa-
tients treated TTFields received a high-dose corticosteroid 
treatment on average (ie, >21.3  mg methylprednisolone 
daily corresponding to >4  mg of dexamethasone daily), 
which has previously been shown correlated with poor 
response to TTFields therapy.26,27 Two of these patients ex-
perienced progression before 6 months, and 2 died before 
1 year of follow-up. The sample size was too low to analyze 
this correlation.
Eight of the 11 patients treated with TTFields had stable 
KPS from inclusion until progression (73%, 95% CI: 
39–94%). Three experienced a KPS decline of 10–20 points 
after resection surgery (27%, 95% CI: 6.0–61%). In 2 of these 
patients, KPS remained stable from surgery until progres-
sion (18%, 95% CI: 2.3–52%), while the final patient experi-
enced a KPS recovery of 10 points during TTFields therapy 
(9.1%, 95% CI: 0.2–41%).
QoL scores were comparable to previous observations,7 
see Supplementary Table S7. The majority of the patients 
had high and constant global (median = 141–167) and func-
tional (median  =  80–89) QoL scores throughout the trial. 
Symptom scores were generally low (median = 8.5–11).
Discussion
In this study, we have evaluated the safety, feasibility, and 
preliminary efficacy of TTFields in combination with tar-
geted SR-surgery against recurrent GBM. The intervention 
introduces skull holes in the vicinity of the tumor to facili-
tate the current flow into the region of interest and thereby 
enhance the TTFields efficacy.
The intervention was well tolerated and we observed 
no SAEs directly attributed to the intervention. SAEs 
were all grade 3 and included fever, fatigue, diarrhea, 
deep vein thrombosis, as well as seizures occurring at 
progression in patients with previously known tumor-
induced epilepsy.
Overall, the most prevalent AE was headache (60% of pa-
tients), whereas minor skin rash of grades 1 and 2 was the 
most common AE in patients treated with TTFields (55%). 
These observations correspond well with previously re-
ported rates10 and AEs were generally easily managed. 
The majority of the AEs were systemic (39%, Table 2 and 
Supplementary Tables S4 and S5) and caused by the dis-
ease or the medical oncological treatment.
With regard to efficacy, we observed positive prelim-
inary signals justifying further investigations. The me-
dian OS was 15.5  months, 95% CI  =  9.4%–NA, which is 
a considerable improvement compared to the 9 months 
commonly reported for patients receiving comparable 
second-line oncological treatment alone.32,33 Furthermore, 
this survival benefit was larger than the expected effects 
caused by the addition of TTFields alone, although our 
study was not powered for comparison with historical 
data. The sole effects of TTFields in the first recurrence 
of GBM were recently investigated in a post hoc analysis 
of the randomized EF-14 trial data (NCT00916409).34 The 
study compared the efficacy of TTFields plus physician’s 
choice chemotherapy with chemotherapy alone after 
the first recurrence. TTFields prolonged the median OS 
by approximately 2 months (11.8 months vs 9.2 months, 
P  =  .049) compared to chemotherapy alone and the au-
thors concluded that the addition of TTFields to medical 
oncological treatment at first disease recurrence is likely 
beneficial. This corresponds with observations from the 
retrospective PRiDe study investigating the real-world 
application of TTFields therapy in recurrent GBM in the 
United States.9 In the PRiDe cohort, approximately 1/3 of 
patients received TTFields after the first recurrence and 
the median OS was 20 months. Collectively, these studies 
indicate that part of our observations could possibly be 
explained by TTFields alone and further randomized 
studies are therefore needed to clarify the potential ef-
fects of using SR-surgery to enhance the dose of TTFields. 
With regard to disease progression, our cohort had a me-
dian PFS of 4.6  months and a PFS6 rate of 36%, which 
is comparable to previous reports of patients treated 
with comparable second-line medical treatment (median 
PFS = 3–4.2 months and PFS6 = 16–41%32,33).
Limitations
Despite promising outcomes, our study was subject to 
important caveats to be considered. Given the small 
sample size, it was not powered for conclusive estima-
tion, confounder adjustment, or direct comparison with 
historical data. Furthermore, our cohort was subject to 
selection bias in the sense that (1) the male/female = 9/2 
ratio was higher than expected, (2) the clinical perfor-
mance was relatively high (median KPS  =  90, range 
70–100), (3) the rate of gross total resection among 
TTFields treated patients was high (9/11), and (4) the 
median TTFields compliance rate was high (90%, range 
48–98), of which the latter 3 are known favorable out-
come predictors.9,35 Therefore, our cohort was expected 
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to perform better than the average population of recur-
rent GBM patients. Furthermore, 2 nonresponders to 
TTFields in our cohort were treated with high doses of 
corticosteroids, which may have potentially reduced the 
efficacy of TTFields.26,27
Also, it should be noted that array placement was based 
on edge effect considerations and general rules of thumb 
and not the standard practice NovoTAL approach. Although 
this approach may have impacted the TTFields efficacy on 
its own, previous studies indicate that such effects would 
likely be considerably less compared to those induced by 
the SR-surgery.16
Future Perspectives
We consider the tested intervention suitable for further 
investigation, and a randomized controlled phase 2 trial 
(NCT04223999) is scheduled to begin recruitment in the fall 
of 2020. The trial includes TTFields in both treatment arms 
and patients are randomized 1:1 to receive SR-surgery or 
not. The trial was designed to test the potential for clinical 
implementation of SR-surgery with TTFields and further 
to shed additional light on the TTFields dose–response 
relationship.
Finally, there is a need for further characterization of 
the effects of different SR configurations, including the 
number, size, and arrangement of burr holes. We are 
currently investigating these aspects with a focus on 
identifying optimal configurations with minimal SR size. 
Our aim is to establish a feasible SR-surgery approach 
based on simple rules of thumb and standard operating 
procedures with priority on clinical utility. These guidelines 
should also address the aspect of optimal array positioning 
when using SR-surgery, which differs from the conven-
tional NovoTAL approach, as discussed above.
Conclusions
SR-surgery offers a rational approach to enhance the 
TTFields intensity for patients with rGBM and potentially 
other brain tumors with TTFields sensitivity. The combina-
tion of TTFields and SR-surgery is safe and nontoxic and 
potentially provides individual benefit with the prolonged 
OS. The trial is the first to prospectively modulate the 
“dose” of TTFields and investigate its impact on safety and 
clinical outcome.
Supplementary Data
Supplementary data are available at Neuro-Oncology 
Advances online.
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